Amid the start of the COVID-19 pandemic, big pharma companies like (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible mobilization on the part of Pfizer and this public health emergency resulted in massive business opportunities for the company.

The Comirnaty COVID-19 vaccine co-owned with BioNTech became the best-selling pharmaceutical product of all time for a single year, topping $40 billion in revenue for 2022. And the anti-viral treatment Paxlovid wasn't far behind at $19 billion.

But now with the World Health Organization recently declaring an end to COVID-19 as a global health emergency, the real questions are as follows: Can Pfizer maintain its business momentum over the long run? And is the stock a buy for income investors? Let's look at Pfizer's fundamentals and valuation to decide.

Continue reading

Source Fool.com